HU · HAN'S UNITED · CLINICAL ARCHIVEFOUNDED 2007 · SHANGRAO
Dossier №
001
/ 010
─── Neurology
Stem cells for cerebral palsy in China: research and rehabilitation
Abstract
Stem cells for cerebral palsy in China: research findings, the role of rehabilitation and limitations. Records and cost questions before travelling to Shangrao.
── Sample 001 · Cerebral palsy · ×400 ──
Cell-based interventions for cerebral palsy are being studied in clinical trials. Some findings are encouraging, but they do not justify promising walking, repair of the injured brain or a specific gain in skills for a child. Rehabilitation remains central to care.
Care planning focuses on daily needs: movement, communication, eating, comfort and family participation. NICE recommends access to multidisciplinary care and goals agreed with the child and family. Physiotherapy, occupational therapy, communication, nutrition and coexisting conditions may require different specialists. These principles remain relevant whether or not the family considers a cell intervention.
Small controlled studies of MSCs alongside rehabilitation have reported improvements in some functional measures. The studies differed in product, participant age, regimen and outcome assessment. Cord blood and cord-tissue cells are different interventions. A positive finding from one study does not establish the efficacy of every cell programme for cerebral palsy.
Before considering a new programme, document current abilities and support needs. Existing GMFCS and GMFM assessments describe baseline function; they are not a test of suitability for cell intervention. Agree goals and repeat assessments with the rehabilitation team. Before-and-after videos or score changes without a controlled comparison cannot separate cell effects from development and rehabilitation.
Small samples and limited follow-up cannot rule out rare or delayed complications. Before consent, obtain product, route, risk and follow-up information. For a trial, request registration and ethics approval. This page does not prescribe intrathecal injections, exosomes or a universal course.
Gather existing neurology and rehabilitation reports, operations, current medicines, seizures, feeding needs and assistance required for transfers. Include previous MRI, EEG and functional assessments if available. Do not arrange new tests solely to submit an enquiry; their need is determined by a clinician. The family may also need accessible accommodation, equipment transport and continuity of care.
What the travel estimate should make clear
A fixed course and its cost cannot be determined by a CP diagnosis alone. Request a written proposal separating medical services, investigations, rehabilitation, accommodation, interpretation and assistance. Clarify the length of stay and follow-up costs after returning home. Links below lead to the enquiry process, general prices and contacts; a published price does not establish an indication for a procedure.
Clinical evidence
Studies and clinical guidance
The study designs and limits of their findings are described below. A publication about a cell product does not automatically establish the efficacy of a particular centre’s programme.
Landmark study01
Developmental Medicine & Child Neurology·2022
Sun JM, et al. (Duke)
Sun JM, et al. Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: An open-label, randomized trial. Dev Med Child Neurol. 2022;64(12):1477-1486.
Open-label randomised trial of different products. Confidence intervals for the primary outcome overlapped substantially; the study was not powered for between-group efficacy comparisons. An exploratory analysis suggested a cord-blood signal, not proof for all MSC programmes.
Gu J, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;11:43.
RCT: 40 enrolled, 39 completed assessment. IV hUC-MSCs with rehabilitation improved ADL, CFA and GMFM more than placebo with rehabilitation. The small sample and 12-month follow-up limit conclusions about long-term benefit and risks.
Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, Lu H
Huang L, Zhang C, Gu J, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant. 2018;27(2):325-334.
Single-blind placebo-controlled study: 54 children completed follow-up. The authors reported GMFM-88 and CFA improvements with MSCs and rehabilitation. Investigators knew group assignments; the result does not prove brain repair or benefit from every cell product.
NICE. Cerebral palsy in under 25s: assessment and management. NICE guideline NG62.
Multidisciplinary CP care: individual goals, communication, nutrition, pain and coexisting conditions. The guideline supports care planning; it does not validate a centre’s cell programme.
This overview of published evidence is for discussion with a clinician. It is not an individual prescription or confirmation of eligibility for a cell intervention.
